Clinical Trial Update: A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

View source ↗

Summary

This clinical trial update reports on progression-free survival and participant experience for metastatic ALK-positive non-small cell lung cancer patients treat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ALK inhibitors (anaplastic lymphoma kinase inhibitors)

Snippet

Sponsor: Takeda | Conditions: Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung | Status: COMPLETED